Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

How I treat patients with myelodysplastic syndromes

(2009) R. M. Stone   BLOOD

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

(2008) Jelena M. Kao et al.   AMERICAN JOURNAL OF HEMATOLOGY

Myelodysplastic syndromes: molecular pathogenesis and genomic changes

(2008) Florian Nolte et al.   ANNALS OF HEMATOLOGY

Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia

(2008) David J. Kuter   Annual Review of Medicine

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

(2008) Mikkael A. Sekeres et al.   JNCI-Journal of the National Cancer Institute

Myelodysplastic syndrome: An update on diagnosis and therapy

(2008) Ahrin Koppel et al.   Current Oncology Reports